**Question:** All of the following are modalities of therapy for hepatocellular carcinoma except

A. Transarterial chemoembolization (TACE)
B. Radiofrequency ablation (RFA)
C. Sorafenib (targeted therapy)
D. Transcatheter Arterial Radioembolization (TARE)

**Correct Answer: A. Sorafenib (Targeted Therapy)**

**Core Concept:** Hepatocellular carcinoma (HCC) is a malignant tumor originating from hepatocytes, the most common form of liver cancer. Treatment modalities for HCC include various approaches depending on the stage and patient's condition.

**Why the Correct Answer is Right:** Sorafenib is a targeted therapy drug, which acts on specific molecular targets involved in tumor growth and angiogenesis. It inhibits the activity of Raf kinase, vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptors (PDGFR), thus suppressing tumor angiogenesis and growth.

**Why Each Wrong Option is Incorrect:**

**A. Transarterial chemoembolization (TACE):** TACE is a treatment that combines chemotherapy with embolization, blocking the blood supply to the tumor. It is a locoregional treatment option for HCC, while Sorafenib is a systemic targeted therapy.

**B. Radiofrequency ablation (RFA):** RFA is a local ablative procedure that uses heat to destroy cancer cells. It is a minimally invasive local therapy for HCC, while Sorafenib is a systemic therapy targeting multiple aspects of tumor growth and angiogenesis.

**C. Transarterial Arterial Radioembolization (TARE):** TARE is a locoregional treatment modality, similar to TACE, combining radioembolization with selective catheterization of tumor-feeding blood vessels. It is a targeted therapy, while Sorafenib is a systemic therapy.

**D. Sorafenib (Targeted Therapy):** As explained above, Sorafenib is a systemic targeted therapy targeting multiple aspects of tumor growth and angiogenesis, while the other options are local therapies for HCC.

**Core Concept:**

Hepatocellular carcinoma is a complex disease involving multiple molecular pathways, including angiogenesis and cell proliferation. The correct answer, Sorafenib, is a targeted therapy targeting these pathways, whereas the wrong options are local therapies for HCC.

**Clinical Pearls:**

1. Choosing the appropriate therapy for HCC depends on factors like tumor size, number, stage, and patient's performance status.
2. Sorafenib is often used in advanced HCC cases, while local therapies like TACE, RFA, and TARE are typically employed for smaller and localized tumors.
3. Combination therapies may be employed in specific cases, as in the case of TACE-plus-RFA.

**Why Each Wrong Option is Incorrect:**

1. TACE involves the administration of chemotherapy drugs into the tumor-feeding arteries, which can cause side effects like liver dysfunction, post-embolization syndrome, and tumor flare phenomenon.
2. RFA